共 50 条
- [1] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II StudyBLOOD, 2019, 134Song, YuqinSong, YongpingLiu, LihongZhang, MingzhiLi, ZhimingJi, ChunyanXu, WeiLiu, TingXu, BingWang, XinGao, SujunZhang, HuilaiHu, YuLi, YanCheng, YingYang, HaiyanCao, JunningZhu, ZunminHu, JiandaZhang, WeiJing, HongmeiDing, KaiyangLu, ZhengguangZhang, BinZhao, RenbinXu, ZhixinZhu, Jun
- [2] Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 studyOncology Research and Treatment, 2015, 38 : 18 - 19Dreyling, M.Wang, M. L.Rule, S.Martin, P.Goy, A.Auer, R.Kahl, B. S.Jurczak, W.Advani, R. H.Romaguera, J. E.Williams, M. E.Barrientos, J. C.Chmielowska, E.Radford, J.Stilgenbauer, S.Jedrzejczak, W. W.Johnson, P.Spurgeon, S. E.Zhang, L.Baher, L.Cheng, M.Beaupre, D. M.Blum, K. A.
- [3] An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Song, YuqinTang, XiaoqiongCai, QingqingLiu, LihongJing, HongmeiJiang, MingSun, XiuhuaWu, JianqiuYang, YuWu, HuijingPeng, ZhigangDing, KaiyangYi, ShuhuaYan, XiaojingWu, GuowuWu, YudanCui, JieOu, PengjuTan, FenlaiZhu, Jun
- [4] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II studyCANCER RESEARCH, 2019, 79 (13)Fowler, Nathan H.Samaniego, FelipeJurczak, WojciechLech-Maranda, EwaGhosh, NilanjanAnz, BertrandPatten, PiersReeves, James A.Leslie, Lori A.Smolewski, PiotrChavez, Julio C.Ghia, PaoloTarella, CorradoBurke, John M.Sharman, JeffKolibaba, KathrynO'Connor, Owen A.Cheah, Chan Y.Miskin, Hari P.Sportelli, PeterWeiss, Michael S.Zinzani, Pier Luigi
- [6] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 StudyBLOOD, 2020, 136Wang, MichaelRule, SimonZinzani, Pier LuigiGoy, Andre H.Casasnovas, Rene-OlivierSmith, Stephen D.Damaj, Gandhi LaurentDoorduijn, Jeanette K.Lamy, ThierryMorschhauser, FranckPanizo, CarlosShah, BijalDavies, AndrewEek, RichardDupuis, JehanJacobsen, EricKater, Arnon P.Le Gouill, StevenOberic, LucieRobak, TadeuszJain, PreeteshBrock, GrahamPatel, PritiTao, LinDlugosz-Danecka, Monika
- [7] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label studyAMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750Deng, LijuanLi, ZhimingZhang, HuilaiHuang, HaiwenHu, JiandaLiu, LihongLiu, TingJin, JieZhu, ZunminLi, WenyuHuang, ZhenqianHuang, WenrongZhou, KeshuYang, HaiyanZhang, MingzhiDing, KaiyangZhou, HuiHu, YuShuang, YuerongCao, JunningGao, SujunLi, DengjuSun, ZiminZhang, QingyuanYi, ShuhuaJi, ChunyanZhang, LianshengHou, ChengDu, YueWang, WeigeZhao, RenbinSong, YuqinZhu, Jun
- [8] GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell LymphomaBLOOD, 2023, 142Phillips, Tycel J.Matasar, MatthewEyre, Toby A.Gine, EvaDe L'Etang, Audrey FilezacByrne, BenLundberg, LindaPadovani, AlejandraBoetsch, ChristopheBottos, AlessiaQayum, Naseer
- [9] GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S515Phillips, TycelMatasar, MatthewEyre, Toby A.Gine, Evade L'Etang, Audrey FilezacByrne, BenLundberg, LindaPadovani, AlejandraBoetsch, ChristopheBottos, AlessiaQayum, Naseer